NewsTOXICOLOGY AND APPLIED PHARMACOLOGYThursday, February 5, 2026 · February 5, 2026
Cyclomulberrin represses renal cell carcinoma progression via ferroptosis activation.
WHY IT MATTERS
Recent peer-reviewed research on Renal cell carcinoma that may be relevant for patients and caregivers.
Renal cell carcinoma (RCC) is one of the most common malignancies in the genitourinary system. Cyclomulberrin (CyM), a natural prenylated flavonoid, has shown anti-tumor potential. However, the efficacy and potential mechanisms of this treatment in RCC remain unclear. This study employed MTT, wound-...
Related conditions
Related news
Int J Circumpolar Health · -222 days ago
A population-based legacy study of myasthenia gravis in Iceland: insights from a small Arctic nation
Published in Int J Circumpolar Health. Hjaltason H et al.…
Ther Adv Rare Dis · -192 days ago
Could an outcome-based agreement be operationalized using real-world data from the Canadian Neuromuscular Disease Registry? Perspectives from an expert-led assessment in spinal muscular atrophy
Published in Ther Adv Rare Dis. Mitha A et al.…
Health Inf Sci Syst · -192 days ago
PhenoRareAI: Phenotype-based intelligent diagnosis for rare neuromuscular disorders of glycogen storage disease and spinal muscular atrophy
Published in Health Inf Sci Syst. Zhai W et al.…
J Allergy Clin Immunol Glob · -39 days ago
Emerging trends and research hot spots in inborn error of immunity: A bibliometric perspective
Published in J Allergy Clin Immunol Glob. Alblooshi H et al.…